- Email: [email protected]
ROLE OF STATIN THERAPY IN PRIMARY PREVENTION OF HEART FAILURE
A56.E532 JACC March 9, 2010 Volume 55, issue 10A
HYPERTENSION, LIPIDS AND PREVENTION ROLE OF STATIN THERAPY IN PRIMARY PREVENTION OF HEART FAILURE ACC Poster Contributions Georgia World Congress Center, Hall B5 Monday, March 15, 2010, 9:30 a.m.-10:30 a.m.
Session Title: Pharmacologic Therapy Abstract Category: Risk Reduction and Rehabilitation Presentation Number: 1131-109 Authors: Jorge E. Silva Enciso, Harikrishna Makani, Jorge Romero, Emad Aziz, Marrick Kukin, Franz Messerli, St. Luke’s Roosevelt Hospital and Columbia University College of Physicians and Surgeons, New York, NY Introduction: The benefits of statins in reducing coronary events, strokes and death from all causes have been well established. They have not been shown to improve morbidity and mortality in patients with overt heart failure (HF). However the role of statins in preventing HF remains unproven. Methods: MEDLINE was searched for all the prospective randomized controlled trials with an average follow up of at least one year comparing statins with placebo or usual care on the incidence of new onset or worsening HF. Overall estimates of effect were calculated using the fixed-effects model since heterogeneity amongst the studies was not significant. Results: 8 studies were retrieved with the total population of 20,054 (79,233 person-years) for statins and 20,087 (79,374 person-years) for placebo/usual care. The risk of new onset or worsening HF was 24% lower in patients with known coronary artery disease (CAD) on statins compared to placebo/usual care group (p<0.00001). However there was no significant difference between the two groups in the reduction of new onset or worsening HF in patients at risk of CAD (p=0.98) or those who already have HF (p=0.93). Conclusions: Statins are beneficial in preventing HF in patients with CAD but fail to provide benefits in those who do not have any evidence of CAD or those who have manifest HF. Too short a follow up may account for the lack of benefit in patients without CAD and too advanced disease progression may account for the lack of benefit in patients with manifest HF.
HYPERTENSION, LIPIDS AND PREVENTION ROLE OF STATIN THERAPY IN PRIMARY PREVENTION OF HEART FAILURE ACC Poster Contributions Georgia World Congress Center, Hall B5 Monday, March 15, 2010, 9:30 a.m.-10:30 a.m.
Session Title: Pharmacologic Therapy Abstract Category: Risk Reduction and Rehabilitation Presentation Number: 1131-109 Authors: Jorge E. Silva Enciso, Harikrishna Makani, Jorge Romero, Emad Aziz, Marrick Kukin, Franz Messerli, St. Luke’s Roosevelt Hospital and Columbia University College of Physicians and Surgeons, New York, NY Introduction: The benefits of statins in reducing coronary events, strokes and death from all causes have been well established. They have not been shown to improve morbidity and mortality in patients with overt heart failure (HF). However the role of statins in preventing HF remains unproven. Methods: MEDLINE was searched for all the prospective randomized controlled trials with an average follow up of at least one year comparing statins with placebo or usual care on the incidence of new onset or worsening HF. Overall estimates of effect were calculated using the fixed-effects model since heterogeneity amongst the studies was not significant. Results: 8 studies were retrieved with the total population of 20,054 (79,233 person-years) for statins and 20,087 (79,374 person-years) for placebo/usual care. The risk of new onset or worsening HF was 24% lower in patients with known coronary artery disease (CAD) on statins compared to placebo/usual care group (p<0.00001). However there was no significant difference between the two groups in the reduction of new onset or worsening HF in patients at risk of CAD (p=0.98) or those who already have HF (p=0.93). Conclusions: Statins are beneficial in preventing HF in patients with CAD but fail to provide benefits in those who do not have any evidence of CAD or those who have manifest HF. Too short a follow up may account for the lack of benefit in patients without CAD and too advanced disease progression may account for the lack of benefit in patients with manifest HF.